Strong clinical outcomes ~1417% weight loss in trials, close to injectable results The oral format may attract patients reluctant to start injections Competitive landscape heats up: Eli Lillys oral rival is now in the spotlight Why it matters for pharma & practice An oral peptide drug shows how innovation opens access Could shift prescribing patterns and market positioning in obesity care Regulatory approval signals growing comfort with complex oral delivery technologies In LMICs like Bangladesh, pills may bypass injection-related barriers once pricing & supply allow Key takeaways for young professionals Innovation + formulation = access expansion QA/QC: oral peptides need precise stability & bioavailability control RA: post-marketing safety and real-world effectiveness will drive future decisions Marketing: convenience is a powerful differentiator when outcomes stay consistent #DrugOfTheWeek #PharmaNews #ClinicalUpdates #PharmaHorizonsBangladesh To view or add a comment, sign in Drug of the Week In the News | Wegovy (Semaglutide) Pill Whats happening now

Not black market, which is springing up everywhere
Snack Food, Satiety, and Weight
During your evaluation, our medical team will determine whether youre more likely to qualify through traditional Medicare Part D or through the Medicare GLP-1 Bridge Program and guide you through the appropriate Prior Authorization process
Number of patients with advanced chronic kidney disease with prescription of GLP1RA and DPP4i
Cannot afford $1,000+ per month for brand-name GLP-1 medications